- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Fisher exact test.
Displaying page 1 of 3.
EudraCT Number: 2016-004460-19 | Sponsor Protocol Number: P1604GTN | Start Date*: 2017-04-20 | |||||||||||
Sponsor Name:G. Pohl-Boskamp GmbH & Co.KG | |||||||||||||
Full Title: A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in... | |||||||||||||
Medical condition: Peripheral arterial occlusive disease (PAOD, femoro-popliteal stenosis) and intermittent claudication (Fontaine stage IIb, pain-free walking distance < 200 m), lasting for at least 3 months to ensu... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017340-14 | Sponsor Protocol Number: RHMCAN0700 | Start Date*: 2011-07-26 |
Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||
Full Title: WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation. | ||
Medical condition: Chronic myeloid Leukemia and acute myeloid leukemia in cytogentic remission | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005143-24 | Sponsor Protocol Number: M14-004 | Start Date*: 2015-07-28 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1... | |||||||||||||
Medical condition: Hepatitis C Virus Infection Human Immunodeficiency Virus Infection Chronic Hepatitis C Compensated Cirrhosis and Non-cirrhotics | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002899-42 | Sponsor Protocol Number: E-L 001 | Start Date*: 2004-12-15 |
Sponsor Name:Dept of Paediatric Anaesthesia, Karolinska University Hospital-Solna | ||
Full Title: Etomidate-Lipuro vs. Diprivan-Propofol with added lignocaine: incidence of injection pain in association with induction of anaesthesia in children. | ||
Medical condition: Any child who is to be anaesthetised for a surgical intervention on an out-patient basis. No specific diagnosis is applicable. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000992-26 | Sponsor Protocol Number: VAPOR002 | Start Date*: 2016-06-29 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Volatile Anesthetic Protection Of Renal transplants 2 | ||
Medical condition: kidney transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) DK (Completed) ES (Completed) NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003707-40 | Sponsor Protocol Number: RD.03.SPR.40031 | Start Date*: 2007-01-09 | |||||||||||
Sponsor Name:Galderma Research and Development SNC | |||||||||||||
Full Title: Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea. | |||||||||||||
Medical condition: Erythemato-Telangiectatic Rosacea (ETR) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002472-99 | Sponsor Protocol Number: EVT302/3009 | Start Date*: 2008-08-12 |
Sponsor Name:Evotec Neurosciences GmbH | ||
Full Title: A phase II multicenter, randomised, double-blind, parallel group, placebo-controlled, study to evaluate the effectiveness of EVT 302 in smoking cessation, effect on its own and in combination with ... | ||
Medical condition: Male or female subjects who are chronic smokers, but motivated to quit smoking will be recruited. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002642-32 | Sponsor Protocol Number: Protocol No. PR-00908 | Start Date*: 2009-01-06 |
Sponsor Name:Warner Chilcott UK Limited | ||
Full Title: A Placebo Controlled, Single-Blind, Pilot Clinical Evaluation of the Effect of a Novel Antibiotic Preparation on the Cutaneous Microflora and Clinical Signs in Acne Patients. | ||
Medical condition: WC3018 will be indicated for the treatment of of mild to moderate acne vulgaris. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000569-61 | Sponsor Protocol Number: CHUBX2016/27 | Start Date*: 2021-12-20 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial | ||
Medical condition: Alzheimer disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002112-27 | Sponsor Protocol Number: MD1003CT2013-01MS-ON | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:MEDDAY SAS | ||||||||||||||||||
Full Title: Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study | ||||||||||||||||||
Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000944-13 | Sponsor Protocol Number: GEN-004-002 | Start Date*: 2014-07-30 | |||||||||||
Sponsor Name:Genocea Biosciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intran... | |||||||||||||
Medical condition: Pneumococcal Nasal Carriage | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004208-37 | Sponsor Protocol Number: S63190 | Start Date*: 2020-08-03 |
Sponsor Name:UZ Leuven | ||
Full Title: Drug repurposing - Statins as microbiota modulating agents in ulcerative colitis | ||
Medical condition: There are two population groups, 20 healthy volunteers and at least 165 individuals diagnosed with IBD. Either with remission to mild/moderate active ulcerative colitis or remission to mild Crohn's... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001431-30 | Sponsor Protocol Number: M05-731 | Start Date*: 2005-07-30 |
Sponsor Name:Abbott GmbH & Co. KG | ||
Full Title: A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (... | ||
Medical condition: HIV-1 infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003158-91 | Sponsor Protocol Number: KRX-101-301 | Start Date*: 2005-10-21 | |||||||||||
Sponsor Name:Keryx Biopharmaceuticals, Inc. | |||||||||||||
Full Title: THE COLLABORATIVE STUDY GROUP TRIAL: THE EFFECT OF SULODEXIDE IN PATIENTS WITH TYPE 2 DIABETES AND MICROALBUMINURIA | |||||||||||||
Medical condition: Type 2 Diabetic Microalbuminuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) GB (Completed) BE (Completed) HU (Completed) ES (Completed) IT (Completed) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002211-10 | Sponsor Protocol Number: GRASPA-TNBC-2018-02 | Start Date*: 2019-03-20 | |||||||||||
Sponsor Name:ERYTECH Pharma | |||||||||||||
Full Title: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone for the Treatment of Patients with Metastatic or Locally Recurrent T... | |||||||||||||
Medical condition: Triple-Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002841-39 | Sponsor Protocol Number: GINECO-OV-222 | Start Date*: 2013-10-07 | |||||||||||
Sponsor Name:ARCAGY GINECO | |||||||||||||
Full Title: A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with rela... | |||||||||||||
Medical condition: Patients with an histologically confirmed diagnosis of ovarian sex-cord stromal tumor in relapse after a platinum-based chemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007672-41 | Sponsor Protocol Number: Protocol B4Z-MC-LYDO | Start Date*: 2008-12-23 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Cont... | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SE (Completed) AT (Completed) FI (Completed) BE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005661-20 | Sponsor Protocol Number: SKP-021-01-11 | Start Date*: 2012-07-13 | |||||||||||
Sponsor Name:PROMO INTERNATIONAL SRL | |||||||||||||
Full Title: A double-blind, randomised, parallel group, active controlled, multicentre study to assess the therapeutic non-inferiority of SKP-021, a 0.3% ketoprofen patch, versus diclofenac sodium patch in pat... | |||||||||||||
Medical condition: patients with painful and inflammatory conditions (e.g.: back pain, bruise, contusion, sprain, strains) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004083-35 | Sponsor Protocol Number: 2017-53 | Start Date*: 2018-03-28 |
Sponsor Name:Assistance Publique Hôpitaux de Marseille | ||
Full Title: A double-blind, randomized, multicenter study evaluating 200 mg versus 600 mg of Mifepristone on pain in voluntary abortion by drug prior to 7 SA. DoMy Study | ||
Medical condition: patient of 18 years or more, wishing an abortion with medication before 7 weeks of amenorrhea | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000199-25 | Sponsor Protocol Number: 009436 | Start Date*: 2014-04-22 |
Sponsor Name:Queen Mary, University of London | ||
Full Title: A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX-427) in advanced squamous cel... | ||
Medical condition: Advanced squamous cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
